Table 2

Characteristics of participants who did or did not survive the first year after diagnosis

Patient characteristicSurvivalp Value*
<1 year from diagnosis>1 year from diagnosis
Number (%)Number (%)
Age at diagnosis (years)
 <5088 (9.0)3712 (26.4)<0.001
 50–5991 (9.3)3648 (26.0)
 60–69148 (15.1)2894 (20.6)
 70–79270 (27.6)2373 (16.9)
 ≥80383 (39.1)1430 (10.2)
Ethnicity
 Non-white75 (7.7)1983 (14.1)<0.001
 White488 (49.8)8610 (61.3)
 Not known417 (42.6)3464 (24.6)
Distant metastases at diagnosis
 No312 (31.8)7977 (56.7)<0.001
 Yes156 (15.9)271 (1.9)
 Not known512 (52.2)5809 (41.3)
Tumour size (mm)
 <1012 (1.2)1220 (8.7)<0.001
 10–1973 (7.4)4016 (28.6)
 20–3983 (8.5)3103 (22.1)
 40–4986 (8.8)1953 (13.9)
 ≥5099 (10.1)799 (5.7)
 Not known627 (64.0)2966 (21.1)
Node status
 Negative95 (9.7)5492 (39.1)<0.001
 Positive167 (17.0)4213 (30.0)
 Not known718 (73.3)4352 (31.0)
Charlson Index (comorbidities)
 0 (minor)203 (20.7)6755 (48.1)<0.001
 1 (moderate)48 (4.9)359 (2.6)
 ≥2 (severe)231 (23.6)1384 (9.8)
 Not known498 (50.8)5559 (39.5)
Diagnosis date (in relation to Cancer Plan)
 Pre 2000624 (63.7)9057 (64.4)0.79
 2000–2003292 (29.8)3897 (27.7)
 Post 200364 (6.5)1103 (7.8)
Presentation
 Screening23 (2.3)2274 (16.2)<0.001
 Symptoms763 (77.9)9531 (67.8)
 Incidental64 (6.5)528 (3.8)
 Not known130 (13.3)1724 (12.3)
Surgery
 No489 (49.9)1513 (10.8)<0.001
 Yes491 (50.1)12 544 (89.2)
Radiotherapy
 No454 (46.3)3395 (24.2)<0.001
 Yes256 (26.1)7079 (50.4)
 Not known270 (27.6)3583 (25.5)
Chemotherapy
 No520 (53.1)6482 (46.1)<0.001
 Yes203 (20.7)4200 (29.9)
 Not known257 (26.2)3375 (24.0)
Tamoxifen
 No172 (17.6)2321 (16.5)0.49
 Yes601 (61.3)8630 (61.4)
 Not known207 (21.1)3106 (22.1)
Total cases98014 057
  • * p Value for comparison of proportions, excluding ‘not known' category where present. For age, tumour size, Charlson Index and Cancer Plan, test is for trend; for all other factors, test is for heterogeneity.